FMEDFidelity Disruptive Medicine ETF
Seeks long-term growth of capital.
By Fidelity Investments · Launched 2020
Annual Cost
0.50%
#2,667 of 5,861 · average
Fund Size
$46M
#3,718 of 5,861 · mid-size
Return (1Y)Goal
+16.8%
Track Record
6 years
#2,041 of 5,861 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$11,827+18.3%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Active selection
Sector
Health careFocus
General Innovation
What it actually holds
By weightConcentration
Top 10 holdings = 44.6% of fundmoderately concentrated
Fidelity Revere Street Trust
12.6%
DANAHER CORP
4.2%
UCB SA
4.1%
BOSTON SCIENTIFIC CORP
4.0%
ARGENX SE
3.8%
COGENT BIOSCIENCES INC
3.8%
ALNYLAM PHARMACEUTICALS INC
3.3%
INTUITIVE SURGICAL INC
3.1%
VEEVA SYS INC
3.0%
INSULET CORP
2.6%
Asset allocation
Stocks
98.6%
Cash
19.5%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
20.0%Moderate
Year-on-year price swings
Max drawdown
-21.8%Moderate
Worst peak-to-trough loss
Sharpe (3Y)
0.09Below average
Sortino (3Y)
0.12Moderate downside risk
Listing
- Exchange
- NASDAQ Global Market, NASDAQ Global Select Market
Full fund details
- Objective
- Seeks long-term growth of capital.
- Strategy
- Normally invests at least 80% of assets in securities of disruptive medicine companies, focusing on innovative developments in the health care sector. The fund may invest in both growth and value stocks of domestic and foreign issuers.
- Inception date
- April 16, 2020
- Fund family
- Fidelity Investments
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at FMED. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04